Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$688.00K$688.00K+10.1% vs Q2 2022 Net Income-$217.08M-$217.08MN/M vs Q2 2022 EPS Diluted$40.14$40.14N/M vs Q2 2022 Operating Income-$159,246,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-23146.2%−19558.5 pt vs Q2 2022
Net margin-31552.5%−27980.8 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end